Summary: Japanese monkey liver contains multiple forms of dihydrodiol dehydrogenase with 3(20)ahydroxysteroid dehydrogenase activity. Here we have puriˆed the major and minor forms (DD1 and DD4) of the enzyme from Cynomolgus monkey liver, and isolated cDNA species for the two enzyme forms by reverse transcription-PCR. The cDNAs encoded proteins comprising of 323 amino acids, in which the sequence identity between DD1 and DD4 was 83z. The sequences deduced from the cDNAs for DD1 and DD4 perfectly matched the partial sequences of peptides derived from the respective enzymes. We also isolated the cDNAs for DD1 and DD4 of Japanese monkey liver, which had almost identical amino acid sequences with those of the respective enzymes of Cynomolgus monkey liver. The monkey DD1s and DD4s showed the highest sequence identity (94z) with AKR1C1 and AKR1C4, respectively, of four isoenzymes of human 3(20)a-hydroxysteroid dehydrogenase, which belongs to the aldo-keto reductase family. The substrate speciˆcity and inhibitor sensitivity of the puriˆed recombinant Cynomolgu monkey DD1 and Japanese monkey DD4 were also essentially identical to those of the recombinant AKR1C1 and AKR1C4, respectively, indicating that DD1 and DD4 are homologues of human AKR1C1 and AKR1C4, respectively. The mRNA for DD1 was detected only in liver, kidney, intestine and adrenal gland among Japanese monkey tissues, and that for DD4 was expressed in liver and kidney. These tissue distribution patterns diŠer from those of human AKR1C1 and AKR1C4, which are expressed ubiquitously and liver-speciˆc, respectively. In addition, no mRNA for an enzyme corresponding to another isoenzyme (AKR1C2) of the human enzyme was detected in livers of the two monkey strains. The results suggest a diŠerence in the metabolism of steroids and xenobiotics mediated by 3(20)ahydroxysteroid dehydrogenase isoenzymes between monkeys and humans.
Introduction
Dihydrodiol dehydrogenase (DD, EC 1.3. 1.20) catalyzes the NADP + -linked oxidation of trans-dihydrodiols of aromatic hydrocarbons to the corresponding catechols, and has been shown to be involved in metabolic activation of the hydrocarbons through auto-oxidation of the catechol products. 1, 2) In mammalian tissues the enzyme exists in multiple forms, which have been shown to be identical with 3a-, 17b-and 20a-hydroxysteroid dehydrogenases (HSDs), aldehyde reductase and W or aldose reductase. [3] [4] [5] [6] [7] [8] [9] However, there are species diŠerences in the number of multiple forms of hepatic DD and in the nature of its major form. For example, only two DDs are detected in rat, whereas more than three DDs have been puriˆed from other species. The major form of hepatic DD is identical with 3a-HSDs in rat 3, 4) and hamster, 5) but with 17b-HSDs in mouse 6) and guinea pig, 7) and NADP + -dependent D-xylose dehydrogenase in pig. 9) In humans, the major form of hepatic DD is 3a-HSD, 10, 11) but it exists as four isoenzymes, which exhibit sequence identity of more than 83z and belong to the aldo-keto reductase (AKR) superfamily. 12) According to the nomenclature for the AKR family, these isoenzymes are named AKR1C1, AKR1C2, AKR1C3 and AKR1C4, which correspond to previously known 3 (20) a-HSD, 13) 3a-HSD type 3, 14) 3a-HSD type 2, 15, 16) and 3a-HSD type 1, 15, 17) respectively. These isoenzymes diŠer in their a‹n-ity for steroidal substrates, inhibitor sensitivity and eŠects of activators, but exhibit bifunctional activities of 17b-and 20a-HSDs. 18) AKR1C1 is also called 20a-HSD because of its high 20a-HSD activity, 19) and AKR1C3 has been demonstrated to be identical with 17b-HSD type 5 20) and prostaglandin F synthase. 21, 22) In addition, all the isoenzymes, except AKR1C3, reduce ketone-containing drugs, although the substrate speciˆcity for drugs diŠers among the isoenzymes. 23, 24) Monkeys are often used as experimental animals to assess the metabolism and pharmacokinetics of drugs. DD exists in four multiple forms (DD1-DD4) in Japanese monkey liver. DD1 and DD2 have been thought to be the major and minor forms of indanol dehydrogenase, and DD3 and DD4 are identical with aldehyde reductase and 3a-HSD, respectively. 25) A subsequent study on the substrate speciˆcity of DD1 showed that the enzyme possesses 3(20)a-HSD activity. 26) Thesê ndings have suggested that monkey liver DDs correspond to human 3a-HSD isoenzymes. However, there has been no report of the sequences of the monkey DDs, and their properties including substrate speciˆcity, and the eŠects of inhibitors and activators have not been well studied compared to those of the human enzymes, AKR1C1-AKR1C4. Here, we have isolated cDNA species for DD1 and DD4 from livers of both Cynomolgus and Japanese monkeys, and examined the properties of the recombinant enzymes and the tissue distribution in Japanese monkey.
Materials and Methods
Materials: Monkey tissues were obtained from the Primate Research Institute, Kyoto University (Inuyama, Japan). Lysylendopeptidase (LysC) and isopropyl b-Dthiogalactopyranoside were obtained from Wako Pure Chemicals (Osaka, Japan); Pfu DNA polymerase and Escherichia coli cells were from Stratagene; SuperScript II reverse transcriptase and rapid ampliˆcation of cDNA ends (RACE) kits were from Gibco-BRL; original TA cloning and pCR T7 W CT-TOPO TA cloning kits were from Invitrogen; and Taq DNA polymerase and DNA-modifying enzymes were from Takara Shuzou (Kusatsu, Japan). Pyridine nucleotide coenzymes were purchased from Oriental Yeast Co. (Tokyo, Japan); prostaglandin D2 was from Cayman Chemicals (MI, USA); and [9,11,12- 3 H]5a-pregnan-3a-ol-20-one (65 Ci W mmol) was from Daiichi Pure Chemicals (Tokyo, Japan). Medazepam, estazolam, and befunolol were gifts from Nippon Roche Co. (Tokyo, Japan), Takeda Pharmaceutical Co. (Osaka, Japan), and Kaken Pharmaceutical Co. (Tokyo, Japan), respectively. Other substrates, inhibitors and activators were obtained from Sigma Chemicals and Fluka Chemie AG.
Protein sequencing: DD1 and DD4 were puriˆed from Cynomolgus monkey liver according to the procedures for the puriˆcation of the enzymes of Japanese monkey liver, 25) and designated as cyDD1 and cyDD4, respectively. The enzymes were digested with LysC or cleaved by BrCN after reductive S-alkylation, and the peptides isolated on reverse phase HPLC were sequenced by automated Edman degradation with a 473A protein sequencer (Applied Biosystems) as described previously. 17) cDNA isolation: Preparation of total RNA from livers of Cynomolgus and Japanese monkeys, and reverse transcription (RT) were carried out as described previously. 21) Two partial cDNAs for cyDD1 and cyDD4 were ampliˆed from the single-strand cDNAs by PCR using Pfu DNA polymerase, and forward and reverse primers ( Table 1) . Because the peptide sequences of cyDD1 and cyDD4 were similar to the sequences of human AKR1C1 and AKR1C4, respectively, the forward and reverse primers were designed to anneal the sequences outside the putative open reading frames of the cDNA species for the two monkey enzymes based on the nucleotide sequences of the corresponding regions of the cDNAs for the human enzymes. A 936-bp fragment ampliˆed using a pair of primers, HD1f and HD1r, was conˆrmed to be a partial cDNA for cyDD1 by nucleotide sequencing.
17) The 3?-and 5?-ends of the cDNA were generated using the 3?-and 5?-RACE kits and gene-speciˆc primers (Table 1) . Similarly, a cDNA for cyDD4 was generated by RT-PCR using primers (HD4f and HD4r), followed by RACE-PCR. The sequences of the coding regions in the cDNAs were re-examined by sequencing the cDNAs, which had been ampliˆed from the single-strand cDNA sample obtained with Pfu DNA polymerase, and primers corresponding to the regions near the 3?-and 5?-ends of the coding regions (MD1f and MD1r for cyDD1 cDNA, and MD4r and MD4f for cyDD4 cDNA). cDNA species for Japanese monkey DD1 (jpDD1) and DD4 (jpDD4) were ampliˆed from the total RNA sample of the monkey liver by RT-PCR using a set of primers (MD1f and MD1 for DD1 cDNA, and MD4r and MD4f for DD4 cDNA).
Expression and puriˆcation of recombinant DDs: The cDNAs for cyDD1 and jpDD4 were inserted into pCR T7 W TOPO expression plasmids using a pCR T7 W CT-TOPO TA cloning kit. The constructs were transformed into E. coli BL21(DE3)pLysS. The E. coli cells were cultured in 1 liter of LB medium containing ampicillin (50 mg W mL) and chloramphenicol (50 mg W mL) at 379 C until the turbidity reached 0.4. Then, 1 mM isopropyl b-D-thiogalactopyranoside was added and growth of the culture was continued for 6 h. A cell extract was prepared as described previously.
27) The proteins in the extract were fractionated by adding (NH4)2SO4, and the precipitate obtained between 35 and 70z (NH4)2SO4 saturation was dissolved in 20 mM potassium phosphate, pH 7.0, containing 0.2 M KCl, and dialyzed against the buŠer. The enzyme was applied to a Pharmacia Sephadex G-100 column (4.8×80 cm) equilibrated with the same buŠer. The enzyme fractions were concentrated by ultraˆltration with an Amicon YM-10 membrane, dialyzed against 20 mM Tris-HCl, pH 8.5, and then applied to an Amicon Matrex Red-A column (2.0×6 cm) equilibrated with the buŠer. The column was washed with the buŠer containing 0.1 M NaCl, and the enzyme was eluted with the buŠer containing 0.1 M NaCl and 0.5 mM NADP + . At this step, cyDD1 was puriˆed to homogeneity, but the jpDD4 preparation contained some other proteins. The jpDD4 fractions were dialyzed against 5 mM Tris-HCl, pH 8.0, and further puriˆed by chromatography on a Pharmacia Q-Sepharose column (2×20 cm) equilibrated with the buŠer. The enzyme was eluted with a linear gradient of 0-0.1 M NaCl in the buŠer. All the above puriˆca-tion procedures were performed at 49 C, and the buŠers were supplemented with 0.5 mM EDTA, 5 mM 2-mercaptoethanol and 20z (v W v) glycerol to stabilize the enzymes.
Recombinant AKR1C1 28) and AKR1C4 27) were prepared and puriˆed as previously described. Protein concentrations were determined by Bradford's method 29) using bovine serum albumin as the standard.
Enzyme assays: The dehydrogenase and reductase activities of the puriˆed enzymes were assayed by measuring the rates of changes in ‰uorescence (at 455 nm with excitation at 340 nm) and absorbance (at 340 nm), respectively, of NADPH. The standard reaction mixture for dehydrogenase activity consisted of 0.1 M potassium phosphate buŠer, pH 7.4, 0.25 mM NADP + , 1.0 mM S-(+)-1,2,3,4-tetrahydronaphth-1-ol (Stetralol) and enzyme, in a total volume of 2.0 mL. The activity during the puriˆcation was assayed with 0.1 M glycine-NaOH buŠer, pH 10.0, instead of the phosphate buŠer. The reductase activity for carbonyl compounds was determined with 0.1 M potassium phosphate buŠer, pH 7.0, and 0.1 mM NADPH as the buŠer and coenzyme, respectively. The substrates, inhibitors and activators, which were insoluble in water, wereˆrst dissolved in methanol, and then added to the reaction mixture, in which theˆnal concentration of methanol was less than 2.5z. The concentration of methanol did not aŠect the activity of the monkey and human enzymes. One unit of enzyme activity was deˆned as the amount that catalyzed the formation or oxidation of 1 mmol of NADPH per min at 259 C. The apparent Km and Vmax values for substrates were determined by Lineweaver- Fig. 1 . SDS-PAGE of puriˆed DDs. The liver (native) and recombinant (recom.) enzymes (each 2 mg), and molecular mass standards (M) were run on a 12.5z polyacrylamide slab gel, and then stained with Coomassie brilliant blue R-250.
Burk analysis with the following diŠerent concentrations: alicyclic alcohols (0.002-1.0 mM), androstanes (0.2-40 mM), pregnanes (0.1-10 mM), and non-steroidal carbonyl compounds (0.5-50 mM). Unless otherwise noted, the kinetic values are the means of at least three determinations.
Product identiˆcation: The products of the oxidoreduction of [ 3 H]-labeled 5a-pregnan-3a-ol-20-one and reduction of 5a-pregnane-3,20-dione were identiˆed by TLC analysis as described previously.
30)
Results Peptide sequences of monkey DDs and isolation of their cDNAs: The 105,000×g supernatant of the homogenate of Cynomolgus monkey liver showed high S-tetralol dehydrogenase activity, 0.13 unit W mg, and on the subsequent chromatography on a Q-Sepharose column the activity was separated into three peaks, which correspond to DD1, DD2 and DD4 of Japanese monkey liver. 25) The activity yields for the three peaks, designated as cyDD1, cyDD2 and cyDD4, were 67, 3 and 7z, and the substrate speciˆcity and inhibitor sensitivity of the DD2 preparation were almost identical to those of DD1, as described for DD2 of Japanese monkey liver. 25) Therefore, cyDD1 and cyDD4 were further puriˆed by consecutive column chromatographic fractionation on Matrex Red A and hydroxylapatite. SDS-PAGE analysis of theˆnal preparations of the two enzymes revealed a single protein band corresponding to 36 kDa. (Fig. 1) .
To obtain structural information on cyDD1 and cyDD4 for subsequent cDNA cloning, 14 LysC-digested peptides and two BrCN-cleaved peptides of the respective enzymes were isolated and sequenced. The peptide sequences of cyDD1 and cyDD4 were quite similar to the regions of the amino acid sequences of human AKR1C1 and AKR1C4, respectively (Fig. 2) . Therefore, we initially ampliˆed cDNA fragments from the total RNA sample of Cynomolgus monkey liver by RT-PCR using primers that annealed the 5?-and 3?-end regions of the coding regions of cDNA for human AKR1C1 or AKR1C4. PCR with a pair of primers, HD1f and HD1r, ampliˆed a 936-bp cDNA fragment, and that with another pair of primers, HD4f and HD4r, yielded an 879-bp cDNA fragment. The peptide sequences of cyDD1 and cyDD4 perfectly matched the regions of the amino acid sequences deduced from the 936-bp and 879-bp cDNA fragments, respectively. Subsequently, the sequences of the full-length cDNAs for cyDD1 (1225 bp) and cyDD4 (1194 bp) were determined by 3?-and 5?-RACE with the gene-speciˆc primers. The two cDNA species, that contained 972-bp coding regions, were also ampliˆed from the total RNA sample of Japanese monkey liver by RT-PCR using primers that annealed the 5?-and 3?-noncoding regions of the cDNAs for cyDD1 and cyDD4. The sequence of the cDNA amplied using primers MD1f and MD4r showed a diŠerence of eight nucleotides from that of cDNA for cyDD1, and the other cDNA ampliˆed with primers MD4f and MD4r diŠered from the cDNA for cyDD4 byˆve nucleotides. The proteins encoded by the former and latter cDNA species of Japanese monkey were designated as jpDD1 and jpDD4, respectively.
The amino acid sequence deduced from the cDNA for cyDD1 was identical to that deduced from the cDNA for jpDD1, with the exception of two amino acid substitutions at positions 35 and 216 (Fig. 2) . There was only one residue substitution at position 23 between the sequences deduced from the cDNAs for cyDD4 and jpDD4. The sequence identity between cyDD1 and cyDD4 or between jpDD1 and jpDD4 was approximately 83z. The monkey enzymes showed high sequence identity with human AKR1C1-AKR1C4 among the AKR family proteins. The sequence identities of the monkey enzymes with AKR1C1, AKR1C2, AKR1C3 and AKR1C4 were 94, 93, 87 and 83z, respectively, for cyDD1 or jpDD1, the respective values being 83, 81, 84 and 94z for cyDD4 or jpDD4.
Puriˆcation and properties of recombinant enzymes: Because the amino acid sequences of cyDD1 and cyDD4 Fig. 2 . Alignment of the deduced amino acid sequences of monkey DDs with human AKR1C1-AKR1C4. Identical amino acid residues between cyDD1 and the other proteins are denoted by hyphens. The underlined regions of the sequences completely matched the sequences of peptides derived from Lys-C digestion (straight line) and BrCN cleavage (wavy line) of cyDD1 and cyDD4 of Cynomolgus monkey liver. The two residues at positions 35 and 216 of the cyDD1 sequence are replaced by Ile and Tyr, respectively, in the jpDD1 sequence, and only one residue replacement of Thr to Ser at position 23 is observed in the sequences of cyDD4 and jpDD4. The nucleotide sequences have been deposited in DDBJ databases under the following accession numbers: AB070209 (cyDD1), AB070211 (cyDD4), AB070210 (jpDD1), and AB070212 (jpDD4).
were almost identical to those of the respective enzymes of Japanese monkey, recombinant cyDD1 and jpDD4 were expressed from the respective cDNAs in E. coli cells and puriˆed to elucidate the diŠerence in properties between the two types of enzyme. The respective yields (amounts) and speciˆc activities of theˆnal preparations puriˆed from one liter of cultured cells were 35z (10 mg) and 3.9 units W mg for recombinant cyDD1, and 38z (6 mg) and 3.3 units W mg for recombinant jpDD4. The enzyme preparations gave single bands on SDS-PAGE, their molecular masses (36 kDa) being the same as those of cyDD1 and cyDD4 puriˆed from the liver (Fig. 1) .
The two monkey enzymes oxidized both 3a-and 20a-hydroxysteroids, but diŠered from each other in the kinetic constants ( Table 2) . While cyDD1 e‹ciently oxidized 20a-hydroxypregnanes among the steroid substrates, jpDD4 exhibited high k cat W K m values for 3a-hydroxypregnanes as well as for 3a-hydroxyandrostanes. cyDD1 accepted S-indan-1-ol, S-tetralol and 4-chromanol as good non-steroidal substrates, whereas jpDD4 showed low kcat W Km values for the non-steroidal substrates, except for R-tetralol and trans-benzene dihydrodiol. cyDD1 and AKR1C1 also exhibited low dehydrogenase activities toward 5a-androstan-17b-ol-3-one (apparent kcat values of 0.05 and 0.04 min "1 , respectively), but the 17b-HSD activity was not detected for jpDD4 or AKR1C4. In the reverse reaction, cyDD1 reduced all the steroidal and non-steroidal substrates listed in Table 3 , and showed higher kcat W Km values for 3-and 20-ketopregnanes than for 3-ketoandrostanes. In contrast, jpDD4 did not exhibit signiˆcant reductase activity toward progesterone, befunolol or prostaglandin D2, and reduced both 3-ketoandrostanes and 3-ketopregnanes more highly than 20-ketopregnanes. Because cyDD1 and jpDD4 exhibited high sequence identity with human AKR1C1 and AKR1C4, respectively, the kinetic constants of the monkey enzymes were compared with those of the human enzymes that were determined under the same conditions. The substrate speciˆcities of the two monkey enzymes were essentially identical to those of the respective human counterparts, except that jpDD4 showed higher kcat values for most of the substrates than AKR1C4 did. It should be noted that jpDD4 and AKR1C4, but not cyDD1 and AKR1C1, showed high substrate inhibition by the 20a-hydroxypregnanes and 20-ketopregnanes at concentrations of above 3-7 times the respective Km values.
To conˆrm the bifunctional activities of the monkey enzymes, the products of the enzymatic oxidation and reduction of representative substrates were analyzed by TLC. When cyDD1 and jpDD4 were incubated with [ 3 H]-labeled 5a-pregnan-3a-ol-20-one, 5a-pregnane-3,20-dione and 5a-pregnane-3a,20a-diol were detected as the products of oxidation and reduction, respectively. On the reduction of 5a-pregnane-3,20-dione by cyDD1 and jpDD4, both 20a-hydroxy and 3a-hydroxy metabolites were initially produced by cyDD1 and jpDD4, respectively, and then 5a-pregnane-3a,20a-diol was formed on prolonged incubation, as observed with AKR1C1 and AKR1C4.
EŠects of inhibitors and activators: Phenolphthalein, 1,10-phenanthroline and the drugs listed in Table 4 have been reported to inhibit human AKR1C1 and a) The dehydrogenase activity was assayed at pH 7.4, and the kinetic values of the human enzymes are shown in parentheses. 
3-Ketoandrostanes 5a-Androstan-17b-ol-3-one 11 ( na, no signiˆcant activity was detected with 10 mM substrate.
c)
The k cat values were calculated with the activities for 10 mM substrate.
353 Monkey Dihydrodiol Dehydrogenases AKR1C4. 10, 13, 27, 28) These inhibitors also inhibited cyDD1 and jpDD4. When other compounds tested as inhibitors of the enzymes, 3?,3!,5?,5!-tetrabromophenolphthalein (TBPP) and benzbromarone were found to be more potent inhibitors of AKR1C1 and cyDD1 than the known inhibitors. In addition, o-cresolphthalein was a potent inhibitor of AKR1C4 and jpDD4. No signiˆcant diŠer-ence in the IC50 (concentration required for 50z inhibition) values for all the inhibitors was observed between cyDD1 and AKR1C1, or between jpDD4 and AKR1C4. AKR1C4 has been reported to be activated by sulfobromophthalein (BSP), cloˆbric acid derivatives 28) and thyroxines.
31) The activators of AKR1C4 enhanced the dehydrogenase activity of jpDD4, but not that of cyDD1.
Tissue distribution: The distribution of DD1 and DD4 in Japanese monkey tissues was assessed by RT-PCR (Fig. 3) . The expression of the jpDD1 transcript was detected in liver, adrenal gland, intestine and kidney, whereas jpDD4 mRNA was detected only in liver The IC 50 values of the human enzymes, shown in parentheses, are taken from previous papers, 10, 13, 27, 28, 30) except that the values for TBPP, o-cresolphthalein and benzbromarone were determined in this study. b) n.i, no signiˆcant inhibition (less than 30z) was observed with 0.1 mM benzodiazepines and 50 mM steroidal anti-in‰ammatory drugs. jpD1Ef and jpD4Er (b) , or the speciˆc primers for b-actin cDNA (c) was performed for the total RNA from the monkey tissues. The PCR products were subjected to electrophoresis on 2z (w W v) agarose gels and visualized by staining with ethidium bromide. Lanes: 1, cerebrum; 2, cerebellum; 3, lung; 4, liver; 5, intestine; 6, adrenal gland; 7, kidney. and kidney. We also examined whether or not an mRNA species for another enzyme similar to AKR1C2 is expressed in Cynomolgus and Japanese monkey livers by RT-PCR using the primers listed in Table 1 and other primers that anneal regions of AKR1C2 cDNA.
32) The DNA sequencing showed that the ampliˆed cDNAs are the same as those for cyDD1 and jpDD1.
Discussion
The present cloning and expression of two cDNAs for DD1 and DD4 of monkey liver indicate that the two enzymes belong to the AKR family and act as 3 (20)aHSDs. DD1 and DD4 show the highest amino acid sequence identity with AKR1C1 and AKR1C4, respectively, among the AKR family proteins. In addition, the substrate speciˆcity and inhibitor sensitivity of cyDD1 and jpDD4 were similar to those of AKR1C1 and AKR1C4, respectively. Thus, DD1 and DD4 are homologues of human AKR1C1 and AKR1C4, respectively. Although DD1 was previously classiˆed as indanol dehydrogenase in the Enzyme Nomenclature system, we propose that the enzyme should be named 3(20)a-HSD because of its high catalytic e‹ciency for steroids with 3(20)a-hydroxy and 3(20)-keto groups. The kinetic constants of cyDD1 and AKR1C1 for these substrates were almost identical, suggesting that the 19 residues diŠerent between the cyDD1 and AKR1C1 sequences are not responsible for substrate binding of the enzymes. On the other hand, the kcat values for most of the substrates of jpDD4 were higher than those of AKR1C4, while the Km values of the two enzymes were similar. This would suggest that some of the 18 residues that diŠer between the monkey and human enzymes are important for proper orientation of substrates to achieve high catalytic turnover with a minimal eŠect on substrate a‹nity.
In humans, two further 3a-HSDs, AKR1C2 and AKR1C3, have been identiˆed. [14] [15] [16] Recently, a cDNA for monkey type 5 17b-HSD, which exhibits high amino acid sequence identity with AKR1C3, has been cloned, 33) although it remains unknown whether or not the recombinant enzyme possesses the activities of 3a-HSD and prostaglandin F synthase, 21, 22) which are characteristics of human AKR1C3. Thisˆnding, together with the present identiˆcation of monkey homologues of AKR1C1 and AKR1C4, suggests the possibility that a homologue of AKR1C2 is also expressed in monkey tissues. The amino acid sequences of AKR1C1 and AKR1C2 are extremely similar (they diŠer only by seven residues), 13, 14) and mRNA for AKR1C2 is ubiquitously expressed in many human tissues. 18, 32) Considering the high nucleotide sequence identity between DD1 and AKR1C1, and between DD4 and AKR1C4, it should be possible to amplify a cDNA for a monkey homologue of AKR1C2 by RT-PCR with the primers for cyDD1 or other primers that anneal regions of AKR1C2 cDNA. 32) However, no cDNA fragment distinct from that for DD1 was ampliˆed from the total RNA samples of Cynomolgus and Japanese monkey livers by RT-PCR with these primers. The minor form (DD2) in Japanese monkey liver seems to be a candidate for monkey homologue of AKR1C2, but it has been suggested to be a product of post-translational modiˆ-cation of DD1. 25) In addition, the substrate speciˆcity and inhibitor sensitivity of the partially puriˆed DD2 preparation of Cynomolgus monkey liver were almost identical to those of cyDD1. The similarity in the properties of DD1 and DD2 is in contrast to the reports that AKR1C1 shows steroid speciˆcity and inhibitor sensitivity distinct from those of AKR1C2. 13, 14, 18, 30) Therefore, a homologue of AKR1C2 may not exist at least in the livers of the two strains of monkey, although we cannot rule out its expression in other tissues.
DD1 was the major form of DD in Cynomolgus monkey liver as reported on puriˆcation of this enzyme form as DD 25) and indanol dehydrogenase 26) from Japanese monkey liver. The high expression of DD1, the homologue of AKR1C1, in monkey liver is an additional diŠerence from in the case of human liver, in which at least AKR1C1, AKR1C2 and AKR1C4 are expressed almost equally at the mRNA 18) and activity 10, 11) levels. In addition, the distribution pattern of the jpDD1 transcript in Japanese monkey tissues diŠers from the ubiquitous expression of the AKR1C1 transcript in human tissues. 18, 34) Furthermore, the detection of the jpDD4 transcript in both liver and kidney is diŠerent from the liver-speciˆc expression of AKR1C4. Thus, the diŠerences in tissue distribution of the two types of enzyme between humans and Japanese monkeys suggest that their contributions in each tissue to the metabolism of steroids and xenobiotics diŠer between the two primates.
Finally, it is interesting to note that benzbromarone and TBPP are potent inhibitors of both AKR1C1 and monkey DD1. The inhibitory selectivity for the enzymes is further supported by our preliminaryˆnding that the two compounds weakly inhibit the activities of AKR1C2, AKR1C3 and several other members of the AKR family (Y. Higaki and N. Usami, unpublished results). Thus, the two compounds may be useful inhibitors for discriminating AKR1C1 and DD1 from the other isoenzymes or multiple forms of 3aHSD with DD activity in human and monkey tissues. In addition, benzbromarone is clinically used for the treatment of hyperuricaemia, and its maximum plasma concentration was reported to be 4.8 mM after the administration of a single oral dose (100 mg) to seven healthy volunteers. 35) Because the IC50 value of the drug for AKR1C1 is much lower than its plasma concentration, long-term therapy with this drug may modulate the metabolism of steroids and xenobiotics mediated by this enzyme.
